88701-96-6 Usage
Type of Drug
Selective Estrogen Receptor Modulator (SERM)
Primary Uses
Treatment and prevention of osteoporosis and breast cancer in postmenopausal women
Mechanism of Action
Binds to estrogen receptors in the body, leading to a decrease in bone resorption and an increase in bone mineral density
Additional Benefits
Reduces the risk of invasive breast cancer in postmenopausal women with osteoporosis
Contraindications
Not recommended for premenopausal women or those with a history of blood clots due to increased risk of developing complications
Target Population
Postmenopausal women with osteoporosis or at risk of breast cancer
Chemical Structure
Consists of a benzoxathiazine ring fused with an oxirane ring and a phenyl group, with an additional dioxide group at the 2,2-position.
Check Digit Verification of cas no
The CAS Registry Mumber 88701-96-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,7,0 and 1 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 88701-96:
(7*8)+(6*8)+(5*7)+(4*0)+(3*1)+(2*9)+(1*6)=166
166 % 10 = 6
So 88701-96-6 is a valid CAS Registry Number.
88701-96-6Relevant academic research and scientific papers
Synthesis of 4-Styryl-1,2,3-benzoxathiazine 2,2-Dioxides, Naphth-1,2,3-oxathiazine 2,2-dioxide and 1,3-Dipolar Cycloaddition of 1,3-Diphenylnitrilimine to 4-Styryl-1,2,3-benzoxathiazine 2,2-Dioxides
Dhar, Durga N.,Bag, Amal K.
, p. 627 - 631 (2007/10/02)
4-Styryl-1,2,3-benzoxathiazine 2,2-dioxide (4a-e) have been synthesized by the reaction of chlorosulphonyl isocyanate with 2'-hydroxychalcone (1a-e). 2-Hydroxy-1-napthaldehyde reacts with chlorosulphonyl isocyanate to give naphth-oxathiazine 2,2-dioxide (9).The 1,3-dipolar cycloaddition of 1,3-diphenylnitrilimine to 4a-e gives the hitherto unreported heterocyclic system (14)
